Biotechnology
Commented by Nico Popp on September 27th, 2023 | 07:10 CEST
Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics
High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!
Read
Commented by Juliane Zielonka on September 22nd, 2023 | 06:50 CEST
Cardiol Therapeutics, BioNTech, BYD - At top speed to new markets
Cardiol Therapeutics is enjoying a remarkable development. The biotech company is now rolling out its ARCHER patient recruitment trial internationally at 35 participating centers. This accelerates research in the development of their therapy to combat myocarditis, a heart inflammation which has been associated with COVID-19 vaccination. For Cardiol Therapeutics, this represents an opportunity to get its therapy approved as an orphan drug. Approval is also at stake for BioNTech. With a multimillion-dollar funding boost, the Company is working on accelerated approval for a vaccine against a virus that caused quite a stir last year. The shortened development time is likely to impress investors. While business nations agree on fighting viruses, they disagree on commodities for the road. The EU would prefer to restrict BYD's successful sales on domestic roads - by imposing tariffs. BYD, meanwhile, is tapping into a completely different market.
Read
Commented by André Will-Laudien on September 18th, 2023 | 06:30 CEST
Unbelievable! Hands off AI, biotech in rebound! Bayer, Defence Therapeutics, Morphosys
The big fall decline is now over. It is always a difficult time, but the so-called "Triple Witching" went relatively smoothly this time. The European Central Bank (ECB), in its first interest rate meeting after the summer break, decided to raise key rates by another quarter point to 4.00%, up from the previous 3.75% in July. At the same time, it lowered its inflation forecast for 2025 and the outlook for economic growth in the Eurozone for the years 2023 to 2025. Economic risks are increasing, but inflation remains the determining factor for interest rates. Expectations that the US Federal Reserve (FED) will announce an interest rate pause at its next meeting on Wednesday have boosted confidence. Last week's big losers were the recently favoured AI stocks Nvidia, Microsoft and C3.ai. However, the biotech sector has recently started to climb again. Where are the opportunities for investors?
Read
Commented by Nico Popp on September 13th, 2023 | 08:30 CEST
Biotech: Poison cocktail or miracle cure? Defence Therapeutics, MorphoSys, Pfizer
Biotech stocks represent both light and dark. At the end of 2020, BioNtech turned the tide of the pandemic with its Comirnaty vaccine. But many shareholders have also had to endure losses. An example of a loss-maker is the share of the SDAX stock MorphoSys. Between 2020 and 2022, the share lost more than 80%. But what were the reasons for the decline? Are there biotech companies that offer better prospects? We shed light on three stocks from the biotech and healthcare sectors.
Read
Commented by Stefan Feulner on September 12th, 2023 | 07:10 CEST
Trend-setting developments at Covestro, Cardiol Therapeutics and 2G Energy AG
The holiday season is drawing to a close. By Tuesday at the latest, when the last German state concludes its school holidays, every investment banker will be back at their screens, closely monitoring the most exciting events on the markets. Despite the summer lull, there have been many impactful events, especially in second-tier companies, which could significantly impact share prices in the near future.
Read
Commented by André Will-Laudien on September 11th, 2023 | 07:30 CEST
The next steps towards cannabis THC legalization are underway! Canopy, Tilray and BioNTech are taking the lead, and Cantourage Group is experiencing dynamic growth
Cannabis has been decriminalized in some countries but legalized in only a few states. In the US, cannabis is fully legalized in states such as California but outright banned in others such as Texas. While medical use is slowly catching on, the use as an intoxicant and cultivation for personal use remains controversial. Stronger momentum could be sparked by the US Department of Health and Human Services (HHS). The authorities are open to a downgrading of the degree of danger in the categorization of the US Drug Enforcement Administration (DEA). We are talking about two steps from Schedule I to Schedule III, which no longer puts THC on a par with common drugs such as heroin, ecstasy or LSD but classifies them as substances with comparatively little psychological dependence. That would be a revolutionary step. Which stocks can benefit?
Read
Commented by Stefan Feulner on September 7th, 2023 | 08:00 CEST
Biotech with tailwind - Newron Pharmaceuticals, Defence Therapeutics, BioNTech
There is a lot of activity in the biotechnology sector, even though the broadly diversified Nasdaq Biotech Index reflects this with a performance of only 1% since the beginning of the year. In addition to the increasing number of acquisitions by Big Pharma, promising technologies from second-tier companies are performing extremely well. Furthermore, the surging COVID-19 statistics are instilling hope in vaccine producers as they aim to revive their slumping sales.
Read
Commented by Armin Schulz on September 6th, 2023 | 08:00 CEST
BioNTech, Cardiol Therapeutics, Bayer - Tiger mosquitoes, and rising Corona numbers bring biotech back in focus
Corona infections are already rising, even though autumn has not even begun. Hospitals are already fearing a high burden during the winter. Gerald Gaß, the Chairman of the Board of the German Hospital Federation, advised high-risk patients, their close contacts and healthcare workers to keep their flu and COVID-19 vaccinations up to date. Due to constant stress triggered by crises and workload-related pressures, the number of heart patients have also increased in recent years. At the end of August, entire neighborhoods and streets in Paris were closed off to spray insecticides against tiger mosquitoes, which spread diseases like dengue and Zika viruses, among others. This is reason enough for us to examine three companies fighting these threats.
Read
Commented by Nico Popp on August 30th, 2023 | 07:00 CEST
Course Rockets of Yesterday - and Tomorrow: Innocan Pharma, BioNTech, Cardiol Therapeutics
According to the information service IQVIA, dietary supplements generate almost EUR 3 billion in sales in Germany - and the trend is rising. More and more people are paying attention to their health and are not satisfied when the doctor says, "You are healthy." In fact, there is still a lot of upside potential for healthy people, too - for example, when it comes to reducing stress, improving sleep or strengthening the body's own defenses. Today, we highlight three stocks that could benefit from increased health awareness.
Read
Commented by Juliane Zielonka on August 24th, 2023 | 07:00 CEST
Defence Therapeutics, Bayer, Palantir - Milestones, Power Shifts and Mishmash
The radiopharmaceuticals market is expected to grow to USD 13.818 billion by 2028. In collaboration with Orano Group, Defence Therapeutics has developed innovative radioactive cancer therapies that destroy cancer at the cellular level, thereby increasing efficacy and minimizing side effects. According to Defence Therapeutics CEO Sebastien Plouffe, this partnership will lead to top-tier therapies in a growing market. Meanwhile, heads are rolling at Bayer, as CEO Bill Anderson has big plans and is replacing key positions with promising candidates. Employees of the British NHS have probably spoken a bit too much. The US company Palantir has been awarded five NHS contracts without competitive bidding and is currently the favorite for a multi-million dollar contract in the healthcare sector. Find out what this means for investors here.
Read